gpiib/iiia

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

Tirofiban (L700462) (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb/IIIa (GP IIb-IIIa).

Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.

Orbofiban, an orally administered antagonist of the platelet GPIIb/IIIa receptor, effectively inhibits platelet aggregation.

Orbofiban TFA is an orally active GPIIb/IIIa platelet receptor antagonist with inhibitory effects on platelet aggregation for the study of unstable coronary syndromes.

Roxifiban, a prodrug of XV459, is an antiplatelet agent with high affinity and specificity for platelet glycoprotein IIb/IIIa complex(GPIIb/IIIa) receptors.

YZ-202 is the free acid form of orbofiban. As a class II GPIIb/IIIa antagonist, YZ-202 has comparable efficacy to class I antagonists (such as XV459 and DMP802) in inhibiting platelet aggregation, but shows lower potential in altering TF-mediated clot formation strength. This suggests that despite similar anti-aggregation efficacy, YZ-202 may exhibit different effects on platelet-fibrin clot contraction.

EMD 132338 is a GPIIb/IIIa antagonist.

PDI-IN-4 (Compound 14d) is a protein disulfide isomerase inhibitor with an IC50 value of 0.48 μM. It prevents platelet aggregation and thrombosis by reducing the activation of GPIIb/IIIa, without causing significant cytotoxicity. PDI-IN-4 is applicable in thrombosis research.

GP1 precursor exhibits high affinity for the GPIIb/IIIa receptors on activated platelets. When labeled with [18F] radioisotope, it serves as a PET tracer to visualize activated platelet aggregation at a molecular level. GP1 precursor is applicable for thrombosis detection.

Cariporide (HOE-642) (HOE-642), an effective NHE1 inhibitor, has inhibitory effects on the degranulation of human platelets, the formation of platelet-leukocyte-aggregates, and the activation of the GPIIb/IIIa receptor (PAC-1).

GR 144053 trihydrochloride is a potent and selective GPIIb/IIIa receptor antagonist (IC50 = 20 nM). It inhibits fibrinogen-mediated platelet aggregation, used for thrombosis and antiplatelet drug discovery research.

Lamifiban trifluoroacetate is an antagonist of the nonpeptide platelet fibrinogen receptor (GPIIb/IIIa).

UR-2922 is an oral antagonist of platelet GPIIb/IIIa. UR-2922 possessed a high affinity for the human platelet receptor (K(d) <1 nM) and a slow dissociation rate (k(off)= 90 min) in vitro. UR-2922 induced no ligand-induced binding sites (LIBS) expression

UR-3216, a prodrug, is a selective and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.